Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

Completed

Conditions studied: Primary Lung Cancer

In brief

The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.

Key facts

Study ID

NCT01830426

Run by

Epic Sciences

People needed

232

Starts

2012-11-01

Expected to finish

2016-01-01

Last updated by the study team

2016-01-22

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Suspected lung cancer
• Planned to undergo tissue biopsy. Tissue biopsy does not need to be limited to an intrathoracic structures. Biopsies of the supraclavicular lymph nodes are allowed
• Age >18

You may not qualify if…

• Patients with history of a separate (not a primary lung cancer) malignancy within past two years.
• Recent history (past two weeks) of trauma (INCLUDING diagnostic surgery, biopsy, etc)
• Prior lung cancer treatment chemotherapy, radiation, surgery, etc. in past two years.
• Inability to provide informed consent.
• Hgb less than 8.

Where it is running

• Moores Cancer Center — La Jolla, California, United States
• Yale University — New Haven, Connecticut, United States
• Billings Clinic Cancer Center — Billings, Montana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.